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Abstract
Background: The worldwide burden of malaria remains a major public health problem due, in part, to the lack of an
effective vaccine against the Plasmodium falciparum parasite. An effective vaccine will most likely require the induction of
antigen specific CD8+ and CD4+ T-cells as well as long-lasting antibody responses all working in concert to eliminate the
infection. We report here the effective modification of a self-assembling protein nanoparticle (SAPN) vaccine previously
proven effective in control of a P. berghei infection in a rodent model to now present B- and T-cell epitopes of the human
malaria parasite P. falciparum in a platform capable of being used in human subjects.
Methodology/Principal Findings: To establish the basis for a SAPN-based vaccine, B- and CD8+ T-cell epitopes from the P.
falciparum circumsporozoite protein (PfCSP) and the universal CD4 T-helper epitope PADRE were engineered into a versatile
small protein (,125 amino acids) that self-assembles into a spherical nanoparticle repetitively displaying the selected
epitopes. P. falciparum epitope specific immune responses were evaluated in mice using a transgenic P. berghei malaria
parasite of mice expressing the human malaria full-length P. falciparum circumsporozoite protein (Tg-Pb/PfCSP). We show
that SAPN constructs, delivered in saline, can induce high-titer, long-lasting (1 year) protective antibody and poly-functional
(IFNc+, IL-2+) long-lived central memory CD8+ T-cells. Furthermore, we demonstrated that these Ab or CD8+ T–cells can
independently provide sterile protection against a lethal challenge of the transgenic parasites.
Conclusion: The SAPN construct induces long-lasting antibody and cellular immune responses to epitope specific
sequences of the P. falciparum circumsporozoite protein (PfCSP) and prevents infection in mice by a transgenic P. berghei
parasite displaying the full length PfCSP.
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Introduction
The worldwide burden of malaria remains a major public
health problem due to the lack of an effective vaccine against
Plasmodium falciparum, the causative agent of the deadliest human
malaria [1]. There is no recombinant or viral based vaccine that
induces long-lasting protective immune responses. Protection
studies conducted using RTS,S as well as other available data,
suggest that a robust antibody response coupled to a vigorous
PfCSP epitope specific CD8+ T-cell response will likely be needed
for a highly effective pre-erythrocytic stage malaria vaccine [2–4].
But the induction of both of these arms of the immune system by
a single vaccine against malaria has been difficult to achieve.
Nanoparticle based vaccines have been shown to be effective in the
induction of immune responses in animal models without the need
for an adjuvant [5–10]. Most of these particles are based on
polymers that encapsulate antigen or create a solid support to
which protein antigens are chemically coupled and therefore do
not necessarily have control over an ordered array presentation of
epitopes.
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We have previously reported using the basic properties of amino
acids and the tenets of structural biology to design a short linear
protein monomer that combines with identical monomers to form
a self-assembling protein nanoparticle (SAPN) with predictable
and controllable conformation and presentation of epitopes.
Furthermore, we demonstrated these SAPN could elicited
a CD4+ T-cell dependent, high titer, long-lived protective
antibody response against a mouse malaria, P. berghei, sporozoite
challenge [11] in mice. We report here modifications of that
original SAPN design to make a vaccine that could be used in
humans against the malaria parasite P. falciparum. This required
change in the core or scaffold to eliminate sequences that might
cross react with human proteins. We also included three previously
identified CD8+ T-cell epitopes from the P. falciparum circumspor-
ozoite protein (PfCSP) as well as copies of the central PfCSP repeat
sequence of four amino acids NANP. Since the target of the
induced immune responses are directed against the single
sporozoite protein, PfCSP, we choose to utilize a transgenic P.
berghei parasite clone that normally infects rodents [12] to test the
efficacy of the vaccines. These transgenic parasites express full
length PfCSP on the surface of the sporozoite stage and infect mice
similar to wild type P. berghei sporozoites thus allowing us to
directly test the functionality of immune responses, both antibody
and cellular, made against the P. falciparum CSP. As control
vaccine constructs we designed monomers that when assembled
would have scaffolds identical to those of the PfCSP-SAPNs but
displaying on their surface the B-cell epitope repeat amino acid
sequence of the P. vivax VK210 CSP [13].
Results
Expression of Monomer Protein and Refolding to Form
a Nanoparticle
The gene for each monomer was cloned into a bacterial
expression plasmid and transformed into E. coli cells for
expression. Purity of the monomer was determined by SDS-
PAGE (Figure 1). After purification the denaturant was removed
and self-assembly of each of the different monomers (Figure 2A)
into nanoparticles was driven by the interaction of the trimeric and
pentameric oligomerization domains creating a-helical rod-like
coiled-coils [14] (Figure 2B). By both transmission electron
microscopy and dynamic light scatter measurements the final
SAPNs had a size of about 40 nm and formed uniform, non-
aggregating particles (Figure 2C, D).
SAPN Vaccines Expressing P. falciparum CSP (PfCSP)
Repeat Region B-cell Epitopes Protect Against
a Transgenic P. berghei Sporozoites Displaying the PfCSP
Following two or three doses of vaccine high titer epitope
specific antibodies to the NANP peptide were produced in both
C57BL/6 and Balb/c mice (Figure 3A). Following challenge with
sporozoites of the Tg-Pb/PfCSP parasite two wks post third dose of
vaccine 90% to 100% of mice were protected compared to 0% in
the unimmunized infectivity control mice (Figure 3B & Table 1).
Because our standard route of SAPN administration, i.p., is not
a route commonly used to deliver vaccines to humans we tested
i.m. administration in parallel experiments. The route of
administration of PfCSP-SAPN made no statistically significant
difference in either the NANP-specific antibody titers observed
(p = 0.45) (Figure 3A) or the levels of protection achieved
(p = 0.99) in either strain of mice tested (Figure 3B).
Protective Antibody Response is Long-lived
One of the most desirable qualities of a vaccine is long-term
induction of an effective immune response. This would be
especially advantageous for a malaria vaccine because in many
areas where malaria is endemic there are periods of high or low
transmission paralleling rainy and dry sessions, respectively. To
investigate how long after immunization with PfCSP-SAPN
protective antibody levels would persist, we immunized mice at
wk 0, 2 and 4 and challenged them either at wk 6, 8, 12, 16, 28, 40
or 52 of the study with the Tg-Pb/PfCSP sporozoites. After the
third dose of vaccine the mice did not receive booster doses of
vaccine nor were they exposed to parasites until the day of
challenge. Mice maintained high antibody titers out to wk 52
(Figure 3C). Even up to wk 40, 75% to 100% of mice were
protected following challenge and 50% of animals were protected
at wk 52 (Figure 3D). One mouse from the wk 16, wk 28 and wk
52 test groups died before challenge from non-malaria, non-
vaccine related causes. Analysis of pre-challenge antibody titers
and avidity index of individual mice revealed that while there was
no significant difference (p = 0.45) in the group mean pre-
challenge antibody titers, those individual mice whose titer
dropped below about 2200 (7.3 mg/ml) (Figure 3C) and avidity
Figure 1. Analysis of purified monomers. (A) Coomassie Blue
stained SDS-PAGE gel of monomer proteins. Lane 1: Molecular weight
marker proteins; Lane 2: PfCSP monomer; Lane 3: PvCSP monomer; Lane
4: PfCSP-KMY monomer; Lane 5: PvCSP-KMY monomer.
doi:10.1371/journal.pone.0048304.g001
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index #0.32 were not protected. All mice with anti-PfCSP-SAPN
antibody avidity index $0.46 were protected (Table 2). Whereas
greater than 95% mice immunized with the PfCSP-SAPN were
protected from a lethal challenge none were protected if the
animals were immunized with SAPN with an identical scaffold to
the PfCSP-SAPN but displaying P. vivax CSP repeat epitopes on its
surface, the PvCSP-SAPN (Figure 4A).
Figure 2. Sequences, formation and structural analysis of SAPN. (A) The amino acid sequences of the monomers used to make the SAPN in
this study. Black: flanking regions (His-tag, thrombin cleavage site, proteosomal cleavage sites, linkers). Green: coiled-coil pentamer domain (Trp-
zipper); Blue: coiled-coil trimer domain; Red: predicted B-cell epitopes of P. falciparum or P. vivax CSP repeat region; Yellow: predicted human HLA
restricted CD8+ T-cell epitopes P. falciparum CSP; Magenta: universal CD4 T-helper epitope (PADRE) as a part of the trimer domain. (B) SAPNs are
formed by the oligomerization of 3- and 5-stranded coiled-coiled domains within a single polypeptide monomer. Shown is the in silico prediction of
the SAPN with icosahedral symmetry. Colors are representative of the sequences as described in (A). (C) Individual nanoparticles are visualized using
transmission electron microscopy. The bar represents 100 nm. (D) The size distribution of the nanoparticles in solution is monitored using dynamic
light scattering.
doi:10.1371/journal.pone.0048304.g002
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SAPN Platform can Present T-cell Epitopes to Induce
Protective CD8+ T-cells
Between 90% and 100% of mice immunized with PfCSP-KMY-
SAPN, and 40–60% of PvCSP-KMY-SAPN-immunized mice
were protected against lethal challenge (Figure 4A). While the
protection in PfCSP-KMY-SAPN immunized mice could be
attributed to both antibody and cell mediated immune responses,
the protection in PvCSP-KMY-SAPN–immunized mice could
only be attributed to a protective cellular response since antibodies
to P. vivax CSP repeat epitopes do not cross-react with epitopes in
P. falciparum CSP repeat region or against the Tg-Pb/Pf-CSP
parasite. To further determine that cells and not antibodies were
responsible for the observed protection in the experiments
involving PvCSP-KMY-SAPN we immunized a strain of MHC
Figure 3. Antibody responses and protective efficacy induced by SAPN vaccinations in Mice. C57BL/6 and Balb/C mice make high titer
antibodies when immunized with the PfCSP SAPN. (A) Mice were given vaccine intraperitoneally (i.p.) or intramuscularly (i.m.) at wk 0, 2 and 4. Titers
were determined 2 wks after each dose. n = 10 per group per experiment; data are representative of one of three independent experiments with
similar results. (B) Two wks post 3rd dose of PfCSP-SAPN, C57BL/6 mice were challenged with 5,000 Tg-Pb/PfCSP, Balb/C with 10,000, Tg-Pb/PfCSP
sporozoites. Shown are three separate experiments with C57BL/6 mice and two experiments with Balb/C mice. n = 10. Infectivity sham control mice
were given PBS. Mice were considered protected if they had no detectable parasitemia by day 15 following challenge. (C) Titer of anti-PfCSP repeat
antibody of the serum from individual mice in each SAPN vaccinated group two days before challenge. The line represents the mean titers of the
individual mice in that group. n = 6 or 7 depending if serum was available. Those SAPN immunized mice that were protected against malaria are
represented by (N); those that developed parasitemia and died by (m). (D) Protection following challenge. At the predetermined time point, from wk
6 to wk 52 of the study, C57BL/6 mice in a select immunized group (n = 6 or 7) and a time matched PBS-sham vaccinated group were challenged with
5,000 sporozoites. Mice receiving PfCSP-SAPN immunization (black bars) and matched sham PBS vaccinated mice (white bars). ***P,0.0001.
doi:10.1371/journal.pone.0048304.g003
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Class1 knockout mice [15] with the SAPN containing the CD8+
T-cell epitopes (Figure 4B). Knockout mice immunized with
PvCSP-KMY-SAPN were not protected from challenge, whereas
wild type mice receiving PvCSP-KMY-SAPN were protected.
Naı¨ve mice that received sera from PfCSP-SAPN or PfCSP-KMY-
SAPN immunized mice survived challenge and mice that received
splenocytes or enriched CD8 T-cells from PfCSP-KMY-SAPN
immunized mice were protected (Figure 5). But neither
splenocytes nor serum from PvCSP-SAPN-immunized mice
conferred protection to naı¨ve mice and mice that received only
serum from PvCSP-KMY-SAPN-immunized mice were not
protected (Figure 5B). However, mice were protected if they
received splenocytes from PvCSP-KMY-SAPN-immunized mice
(Figure 5B). Finally, the passive transfer of highly enriched CD8+
T-cells from the liver and spleens of mice immunized with PfCSP-
KMY-SAPN conferred protection against Tg-Pb/PfCSP sporozo-
ite challenge of naı¨ve recipient mice (Figure 5c). Together, these
experiments strongly indicated that a SAPN vaccine platform
carrying P. falciparum CSP CD8+ T-cell epitopes was capable of
inducing CD8+ T-cells that were directly involved with the
protection against an otherwise lethal challenge of sporozoites.
An additional desirable quality of a malaria vaccine would be
one that had the ability to induce multi-functional [16], long-term
central memory CD8+ T-cells (TLCM) [17] that would accumulate
at the sites of parasite replication [18,19] and hopefully target
infected cells for destruction. To determine if our SAPN vaccine
induced TLCM we investigated the phenotype of antigen-specific
CD8+ T-cells following PfCSP-KMY-SAPN immunization. We
isolated and analyzed the lymphocytes from blood, draining lymph
nodes, spleen and liver from individual mice for phenotypic
markers of memory cells. We found that immunization did not
disturb the homeostatic balance of the naı¨ve T-cell compartment
in the blood, spleen, liver or draining lymph nodes (Figure 6A).
But we did observe the induction of about 2–8% increase over
baseline of effector memory (CD44hiCD62LloIFNc+IL-2+), central
memory (CD44hiCD62LhiIFNc-IL-2+) or long-term central mem-
ory (CD44hiCD62LhiIFNc+IL-2+) CD8+ T-cells in these organs
(Figure 6B–D and Figure S1A–E). The long term central
memory (TLCM) cells specifically responded by producing both
IFNc and IL-2 when exposed in vitro to each of the K, M, or Y
peptides.
Discussion
Our goal for this study was to determine if we could design and
construct a SAPN that could be potentially used in humans to
induce strong immune responses to the human malaria P.
falciparum CSP epitopes. First, we demonstrated that SAPNs could
elicit high-titer, high-avidity, and long-lasting protective antibodies
to epitopes of the repeat region of the circumsporozoite surface
protein of P. falciparum. Second, we established that SAPNs could
induce antigen-specific CD8+ T-cells responses that played an
active role in a protective immune response. These data
demonstrate that unique, structure-designed nanoparticles, ad-
ministered without adjuvant, have the ability to induce both
antibody and cellular responses in mice that, together or
independently, are able to sterilely protect mice against sporozoites
which display on their surface the CSP of the human malaria
parasite P. falciparum.
We had previously reported the use of a SAPN-based vaccine to
induce protective immune responses in a mouse malaria model
Table 1. Consistency of protection against lethal challenge with malaria parasites in mice immunized with PfCSP-SAPNs.
% Protected (no. protected/no. immunized) p-value
Mouse Stain Exp 1 Exp 2 Exp 3 Between Exp To strain control
Balb/c 100(10/10) 100(10/10) nd 0.99 ,0.001
C57BL/6 100(10/10) 90(9/10) 90(9/10) 0.98 ,0.001
Infectivity control Balb/c 0(0/10) 0(0/10) 0(0/10) 0.99
Infectivity control C57BL/6 0(0/10) 0(0/10) nd 0.99
PfCSP-SAPN vaccines were administrated at wk 0, 2 and 4 in three independent experiments Two wks post 3rd dose of PfCSP-SAPN, C57BL/6 mice were challenged with
5,000 and Balb/C with 10,000, Tg-Pb/PfCSP sporozoites. Shown here are three separate experiments with C57BL/6 mice and two experiments with Balb/C mice. n = 10.
Infectivity sham control mice were given PBS. Mice were considered protected if they had no detectable parasitemia by day 15 following challenge. nd = not
determined.
doi:10.1371/journal.pone.0048304.t001
Table 2. Anti-SAPN antibody titer, avidity index and protection in mice immunized with PfCSP-SAPNs.
Mouse ID ELISA Ab Titer Concentration of IgG (ug mL21) Avidity index of Ab Status of protection
#590 3038 9.24 0.46 P
#591 466 6.00 0.32 NP
#592 668 1.75 0.24 NP
#895 6430 16.11 0.55 P
#979 8140 34.94 0.55 P
#980 171 0.09 0.22 NP
Analysis of sera from individual mice immunized with PfCSP-SAPNs for anti-SAPN specific antibody titer, IgG concentration and avidity index vis-a`-vis the protection
status of each mouse. All sera used in this analysis were taken 48 wks post-3rd immunization (wk 52 of study), one day before mice were challenged. P = protected from
challenge dose of transgenic sporozoites. NP = not protected from challenge dose of transgenic sporozoites.
doi:10.1371/journal.pone.0048304.t002
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[11]. However, a part of the core scaffold (designated P4c) in our
early mouse vaccine construct, P4c-Mal could not be used as basis
for a vaccine destined to be used in humans because it contained
sequences corresponding to the human cartilage oligomeric matrix
protein (COMP). Therefore, to develop a SAPN-based vaccine
that could be potentially used in humans, the COMP in P4c was
replaced with a de novo designed high tryptophan content sequence
(Trp-zipper) that, like COMP, formed a pentameric coiled-coil
domain (Figure 7). Surprisingly, this new construct, T81c-Mal,
did not induce antibody production in mice and protection against
parasite challenge was lost. We reasoned that the removed COMP
sequence contained a CD4 helper epitope and therefore we added
the pan-allelic DR epitope (PADRE) [20] into the newly designed
scaffold to make the construct T81c-8-Mal. This restored antibody
production in mice and, subsequently, protection from challenge.
Figure 4. SAPN vaccination induces protective cellular immune responses in mice. SAPN based vaccines present CD8+ T-cell epitopes to
stimulate a protective cellular immune response. (A) C57BL/6 mice immunized with a SAPN containing only P. falciparum CSP B-cell epitopes (PfCSP-
SAPN) or a SAPN containing both P. falciparum CSP B- and T-cell epitopes (PfCSP-KMY-SAPN). n = 10; Error bars show means 6 s.d. of three separate
experiments. (B) Either sera or total splenocytes were transferred from immunized mice to naı¨ve mice which were challenged 24 h post-transfer.
n = 10; data shown is one of two experiments. (C) In order to determine if CD8+ T-cells were involved in protection we immunized wild-type C57BL/6
mice (WT) and MHC Class I knockout (MHC1 KO) mice with SAPN containing PfCSP specific CD8+ epitopes. Mice were challenged with 5,000 Tg-Pb/
PfCSP sporozoites. n = 10. *P,0.01; ***P,0.0001.
doi:10.1371/journal.pone.0048304.g004
Figure 5. Sera or Cell Transfer Studies. (A) Pooled sera isolated from mice immunized with PfCSP-SAPN or PfCSP-KMY-SAPN but not sera from
PvCSP-SAPN or PvCSP-KMY-SAPN immunized mice transferred to naı¨ve mice conferred protection from challenge with Tg-Pb/PfCSP sporozoites. (B) In
a separate experiment sera or washed splenocytes from mice were transferred. Whereas sera from PfCSP-SAPN or PfCSP-KMY-SAPN transferred
protection sera from PvCSP-SAPN or PvCSP-KMY-SAPN immunized mice did not. On the contrary, total splenocytes from PfCSP-KMY-SAPN or PvCSP-
KMY-SAPN transferred protection while splenocytes from PfCSP-SAPN or PvCSP-SAPN did not. (C) Two wks post final immunization with PfCSP-KMY-
SAPN 1.336106 enriched CD8+ T-cells were adoptively transferred to naı¨ve animals which were then challenged 72 hrs post transfer. *P,0.05. Mice
were challenged with 5,000 Tg-Pb/PfCSP sporozoites. n = 10.
doi:10.1371/journal.pone.0048304.g005
Nanoparticle Vaccine to P. falciparum CSP
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e48304
If sporozoites make their way to the liver they can avoid
antibody by entering hepatocytes and undergoing developmental
transformation and replication. In the liver stage of development
CSP is no longer produced therefore all detectable CSP is
a product of the initial invading sporozoite parasite [21]. The CSP
is processed and peptide epitopes are presented on the hepatocyte
surface in the context of MHC Class I molecules [22,23]. It has
been shown that P. yoelii CSP epitope specific CD8+ T-cells can kill
hepatocytes containing developing malaria parasites [24]. But the
induction of CSP-specific CD8+ T-cells using recombinant protein
or a multiple antigenic peptide array vaccine has been difficult to
achieve without the co-administration of a potent immuno-
stimulators that are not suitable for human vaccine development
[25]. Reports have indicated that CD8+ T-cell responses could
also be induced by antigen-containing small particles (20–200 nm)
that are trafficked to the lymph nodes where they are taken up by
antigen presenting cells, processed and presented to adaptive
immune cells [26]. To test if SAPN induced protective CD8+ T-
cells we engineered on to the nanoparticle scaffold three predicted
CD8+ T-cell epitopes (KPKDELDY, MPNDPNRNV &
YLNKQNSL) from the P. falciparum 3D7 clone. The epitopes
were selected because of the prevalence of the human HLA B35,
B7 and A2.1 haplotypes in the world’s population. About 40% of
the world is HLA-A2 [27] with between 35–50% in every ethnicity
in the USA [28]. In addition, the HLA-A2.1, HLA-B7 and HLA-
B35 haplotype associated PfCSP CD8+ T-cell epitopes have all
been associated with protection from malaria in Africans and
other ethnic groups [29–32] thus a vaccine based on these CD8+
T-cell epitopes should have a broad coverage throughout the
world. If the vaccine is tested with a P. falciparum 3D7 clone
challenge, all three CD8 epitopes will be present on the CSP of the
invading sporozoite. However, of the three 3D7 clone epitopes
chosen only one of the sequences, the M peptide, had a 100%
homology match to the PfCSP of the Wellcome strain CSP protein
used in the transgenic parasite model (Table 3). This single 100%
homology match, and perhaps the lower homology matched
epitopes, did however induce protective CD8+ T-cells as
demonstrated by the cell transfer studies presented in Figure 4
and Figure 5. This is encouraging because it suggests that a single
vaccine containing several different HLA specific CD8+ T-cell
epitopes could have broad coverage in a malaria endemic area
with multiple parasite strains.
Figure 6. CD8+ T-lymphocyte population profiles. PfCSP-KMY-SAPN immunized mice show induction of long-lived Ag-specific memory cells
and residency in both secondary lymph and non-lymphoid organs (A–D). Two to five wks post final immunization total lymphocytes from designated
organs were cultured, stimulated with peptides, stained and characterized by flow cytometry. Data are presented as a percentage of the CD8+ T-cell
population normalized to peptide stimulated saline control minus media alone. Data was segregated based on phenotype and location for (A) naı¨ve,
(B) effector memory, (C) central memory, and (D) long-term central memory cell populations and characterized as Naı¨ve, TEM, TCM or TLCM based on
expression levels of CD44, CD62L, IL-2 and IFNc. The FACS gating strategy is shown in Figure S1. Error bars represent the mean 6 s.d. observed in 4
separate experiments, two mice each, over the course of 5 wks post vaccination. LN = lymph node; SPL = spleen.
doi:10.1371/journal.pone.0048304.g006
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One of the more interesting aspects of SAPN formulation is the
ability to trigger immune responses without the need of an
adjuvant. In our previous study we have shown that potential
traces of LPS were not the reason for the adjuvant effect of SAPN
[11]. Furthermore, in vitro studies have shown that SAPN activate
dendritic cells in vitro to over-express the co-stimulatory molecules
CD40 and CD86 (Figure S2). This is consistent with an adjuvant
effect of SAPN. However, the exact mechanisms by which SAPN
activate these dendritic cells as well as the receptor(s) involved in
SAPN recognition by dendritic cells are still unclear and is
currently under investigation.
The promise of vaccination against malaria depends on epitope
selection and delivery to the immune system to induce strong,
long-lasting immune responses. In this study, we performed the
first essential steps to show the ability of a new vaccine platform to
deliver PfCSP B- and T-cell epitopes to induce long-lived humoral
and cellular responses. Certainly the epitope approach would be of
limited value if the selected sequences were highly variable. But,
the central repeat region of the PfCSP is highly conserved. While
there is significant divergence in the CD8+ T-cell epitopes in the
flanking regions we have shown that we can incorporate at least 3
different epitopes, encompassing major HLA haplotypes into the
Figure 7. Schematic representation of redesigning the scaffold for SAPN-based P. falciparum CSP vaccine. The cartilage oligomerization
matrix protein (COMP) was replaced with a de novo designed sequence (Trp-zipper) that, like COMP, forms a pentameric coiled-coil domain.
Sequences coding for the universal CD4 T-cell helper epitope, the pan-allelic DR epitope (PADRE) were incorporated into the trimeric coiled-coil
domain without disrupting the stoichiometry needed to oligomerize. The P. berghei circumsporozoite surface protein repeat (PbCSP) epitopes were
replaced with PfCSP repeat epitopes to form PfCSP-SAPN. Three PfCSP CD8+ T cell epitopes were then engineered into the pentameric coiled coil
domain to form PfCSP-KMY-SAPN.
doi:10.1371/journal.pone.0048304.g007
Table 3. Amino acid sequences of the three predicted P. falciparum CSP CD8+ T-cell epitopes (K, M and Y) based on binding to
major human HLA haplotypes.
Peptide Name K M Y
HLA Restriction B35 B7 A2.1
Sequence in Pf- or PvCSP-KMY-SAPN polypeptide KPKDELDY MPNDPNRNV YLNKIQNSL
Sequence in 3D7 Strain CSP KPKDELDY MPNDPNRNV YLNKIQNSL
Sequence in Wellcome Strain CSP KPKDQLDY MPNDPNRNV YLKKIQNSL
Shown are comparisons to the known sequence in the 3D7 strain of P. falciparum CSP (used for human volunteer challenge trials) and to the Wellcome Strain of P.
falciparum CSP sequence expressed in the Tg-Pb/PfCSP sporozoites (used in these mouse studies). Underlined residues in Wellcome strain highlight the differences from
the 3D7 strain.
doi:10.1371/journal.pone.0048304.t003
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SAPN design which gives the vaccine a wider effective range.
Using protein engineering we can change the vaccine to modify
epitope presentation. For example, several different T-cell epitopes
determined optimal for control of local parasite strains or
improved responses from indigenous human MHC haplotype
populations can be engineered into the monomer sequence to be
assembled into the final vaccine product. The use of rodent
transgenic parasites expressing P. falciparum molecules represented
a powerful and convenient model to dissect and evaluate the
effectiveness of the immune responses against a human malaria
antigen. In future studies with human volunteers we will aim to
demonstrate the safety and immunogenicity of this nanoparticle
malaria vaccine and to test its effectiveness against a challenge of
P. falciparum sporozoites.
Materials and Methods
Ethics Statement
Research with mice was conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals and adheres
to principles stated in the Guide for the Care and Use of
Laboratory Animals, NRC Publication, 1996 edition. All animal
work was conducted under protocols approved by the WRAIR/
NMRC Institutional Animal Care and Use Committee.
Redesign of the Scaffold
The redesign of the core scaffold to be use as the basis for
human SAPN vaccine constructs was as schematically presented in
Figure 7. The DNA sequence encoding the cartilage oligomer-
ization matrix protein (COMP) was replaced with sequence that
encodes a de novo designed Trp-zipper sequence:
WQTWNAKWDQWSNDWNAWRSDWQAWKDDWAR-
WRALWM, that forms a pentameric coiled-coil domain [33]
(Figure 2). Sequences coding for the universal CD4 T-cell helper
epitope, the pan-allelic DR epitope (PADRE) was incorporated
into the trimeric coiled-coil domain without disrupting the
stoichiometry needed to oligomerize followed by a replacement
of the P. berghei circumsporozoite surface protein repeat (PbCSP)
epitopes with PfCSP repeat epitopes to form PfCSP-SAPN. Three
PfCSP CD8+ T-cell epitopes were then engineered on to the
pentameric coiled coil domain to form PfCSP-KMY-SAPN.
P. vivax CSP Containing SAPN
Using the plasmids that expressed the PfCSP-SAPN and PfCSP-
KMY-SAPN monomer proteins we switched the sequences that
encoded the PfCSP repeats for sequences that were designed to
express monomer proteins containing the P. vivax CSP (VK210)
repeat sequence DRAAGQPAGDRADGQPA (Figure 2).
Plasmids, Protein Expression, Purification and
Characterization
Plasmids (pET24 backbone) containing inserted genes to encode
the desired monomer proteins were transformed into BL21 (DE3)
E. coli, Tuner strain, cells and grown in LB Broth to OD600 = 0.8
and induced with 0.5 mM IPTG for 2 h. Cells were collected by
centrifugation and resuspended in 40 mL cold Cracking Buffer
(6 M guanidine-HCl, 20 mM Tris-HCl, 100 mM NaH2PO4,
pH 8.0) and disrupted by a single pass through a high-pressure
microfluidizer (Model 1109; Microfluidic Corp.). The total cell
lysate was centrifuged at 12,000 rpm, 30 min. The monomer
protein was purified from the supernatant by nickel nitrilotriacetic
acid (Ni-NTA)-agarose chelating resin affinity chromatography
followed by two polishing ion-exchange chromatography steps
utilizing an FPLC system (AKTA Purifier, GE Healthcare). The
first, SP-Sepharose, enriched the monomer protein and the
second, Q-Sepharose, bound and removed endotoxin. Through-
out the purification protocol the monomer was kept in a denatured
state by maintaining an 8 M urea concentration in the buffer.
Buffer pH and salt concentrations were changed as required to
retain or elute the monomer protein. All elutions were monitored
by UV absorbance at OD280. The monomers were allowed to
combine into a nanoparticle by dialysis of the final eluted protein
solution against multiple changes of Refolding Buffer (20 mM
Tris-HCl, 5% Glycerol (vol/vol), pH 7.5) to remove the urea. The
nanoparticle size was determined by dynamic light scattering
(DLS) and transmission electron microscopy (TEM) as described
below. Endotoxin contamination of the final sample was de-
termined by the pyrochrome Limulus amebocyte lysate (LAL) test
(Associates of Cape Cod) following the manufacturer’s recom-
mended instructions and was routinely ,10 EU mg21 of protein.
Aliquoted vials of material were quick frozen on dry ice and stored
at 280uC. For use a vial of sample was quickly thawed to RT and
an aliquot was checked by DLS for confirmation of particle
integrity.
Transmission Electron Microscopy
The sample was negatively stained with 1% (wt/vol) uranyl
acetate (SPI Supplies) and observed with a FEI Tecnai T12 S/
TEM at an accelerating voltage of 80 kV (FEI). The protein
concentration of the construct was about 0.05 mg mL21.
Dynamic Light Scattering
DLS experiments were carried out on a Zetasizer Nano S
Instrument (Malvern), with a 633 nm He-Ne laser. All measure-
ments were carried out at RT in the final refolding buffer
containing 20 mM Tris-HCl, pH 7.5 and 5% glycerol (v/v).
Mice
Six-to-eight-wk old female C57BL/6 (H-2b) and BALB/C (H-
2d) mice were used for most protection experiments. In addition,
an MHC Class I (MHC I) knockout (KO) strain (B6.129P2-
B2mtm1Unc/J) was used to determine the role of CD8+ T-cells in the
immune response to the SAPN. All mice were obtained from The
Jackson Laboratory.
Immunization
All mice were immunized either intramuscularly (i.m.) or
intraperitoneally (i.p.) with 10 mg of protein in 0.1 mL of
Refolding Buffer per immunization, on d 0, 14 and 28 unless
otherwise noted.
Challenge with Parasites
A clone of the transgenic P. berghei parasite [12], expressing the
full-length P. falciparum CSP was used. In this transgenic parasite
(Tg-Pb/PfCSP) the endogenous csp gene from P. berghei had been
replaced with the full-length csp gene from P. falciparum thus
allowing testing of responses to both B- and T-cell PfCSP specific
epitopes. The sporozoite of this clone has been previously
demonstrated to invade mouse hepatocytes and initiate a lethal
blood infection in mice [12,34]. Cryopreserved mouse blood
containing infected RBCs of the original clone was injected into
C57BL/6 mice and after 5 days whole blood was isolated and
cryopreserved for future used. For infectious sporozoites an aliquot
of frozen blood stage parasites was thawed and injected into mice.
When gametocytes were observed to be above 3% of infected cells
by stained slide examination Anopheles stephensi mosquitoes were
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allowed to feed on the mice. Sporozoites were isolated after 18–
22 d. C57BL/6 mice were challenged by i.v. injection with 5,000
sporozoites/mouse; Balb/C mice were challenged with 10,000
sporozoites/mouse.
Determination of Infection Following Parasite Challenge
Parasitemia was determined by examining Giemsa-stained thin
smears prepared with blood from each mouse from 6–15 d post-
challenge. Parasitemic animals were euthanized immediately
following detection of blood stage parasites and an animal was
considered fully protected if no parasites were detected by 15 d
post challenge.
Determination of Antibody Titers
Antibody responses against the PfCSP peptide (NANP)6 or
PvCSP recombinant protein VMP001 (containing 9 copies of the
PvCSP VK210 repeat) [35] were measured by the enzyme-linked
immunosorbent assay (ELISA) as previously described [11].
Briefly, 96-well microplates (Dynax) were coated with 100 ng of
the synthetic PfCSP peptide (Eurogentec North America) or 50 ng
of the VMP001, per well, overnight at 4uC and then blocked for
1 h at 37uC with BlockerTM Casein in PBS (Thermo Scientific
Inc). Plates were washed three times (PBS, 0.05% Tween20) and
incubated for 1 h at 37uC with individual mouse sera in duplicate
wells per serum sample. Plates were washed again and incubated
for 1 h at RT with 1:5,000 diluted (106 diluted solution of
BlockerTM Casein in PBS) secondary anti-mouse immunoglobin
(total IgG, IgM and IgA) labeled with horseradish peroxidase
(Southern- Biotechnology Associates). Plates were washed and
developed by adding 2, 29-azino-di (3-ethylbenthiazoline sulfo-
nate)-peroxidase (ABTS) substrate (Kirkegaard & Perry Labora-
tories) for 1 h at RT. The reaction was measured using a BioTek
SynergyTM 4 Microplate reader by determining optical density at
405 nm (OD405). Antibody titers were determined as the dilution
which gave an OD405 = 1 by the SoftMax Pro v5.2 ELISA
Analysis Software (Molecular Devices LLC).
Determination of Concentration of Antibody
Serum from immunized mice were diluted to 1:500 and
incubated for one hour with Luminex microspheres covalently
coupled with the CS repeat peptide [(NANP)7]. After washing,
microspheres were incubated for an additional hour with 100 ml of
goat anti-mouse IgG-PE (Jackson ImmunoResearch). Samples
were analyzed by LuminexH 200TM (Luminex Corporation,
Austin, Tx) and the antibody concentration (mg/mL) interpolated
from an 8-point standard curve prepared using dilutions of
a monoclonal antibody with known concentration.
Determination of anti-SAPN Antibody Avidity Index (AI)
The AI of anti-SAPN antibodies was determined as previously
described [11]. Briefly, concentration of sodium isothiocynate
(NaSCN) that eluted 50% of the total bound IgG was first
determined. Then, two duplicate serial dilutions for a second
ELISA were done (in duplicate wells) on a single plate. After three
washes with PBS-T and one wash with PBS, 100 mL NaSCN
(1.5 M, dissolved PBS) was added to one set of the serial dilutions
on the plate and plain PBS to the other dilution series. After
15 min incubation, all wells were washed and developed as
described above. The AI was calculated based on the ratio of the
areas derived from under the curves obtained by the plot of optical
density (OD405 nm) and log of the sera dilution in the ELISA
experiment with and without NaSCN treatment.
Adoptive Transfer of Serum or Cells
Serum or cells (total splenocytes or enriched CD8+ T-cells) were
harvested two wks after the third immunization from mice for the
adoptive transfer experiments. 100 mL of pooled serum (non-
diluted) from immunized or non-immunized (injected with saline)
mice was transfused to each of five 6–8 wk old naı¨ve C57BL/6
female mice. Single cells suspensions were made from organs of
immunized or saline control mice. CD8+ T-lymphocytes were
enriched from the liver and spleens of immunized mice with
a lineage depletion kit (the cocktail of antibodies was against CD4,
CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105,
Anti-MHC Class II, and Anti-Ter-119 (Miltenyi Biotec)). Using
antibodies to CD3e, CD4 and CD8 it was determined by flow
cytometry that .98% of the enriched cells were CD8+ T-
lymphocytes. A total of 206106 total splenocytes or 1.336106
enriched CD8+ T-cells were intravenously injected into naı¨ve
C57BL/6 mice. Mice were challenged with 5,000 sporozoites 24 h
after receiving total splenocytes or 72 h after receiving enriched
CD8+ T-cells.
In vitro Cell Stimulation, Surface and Intracellular Staining
To assess cell profiles following in vitro stimulation with either
KPKDELDY (K), MPNDPNRNV (M), or YLNKIQNSL (Y)
peptides, single cell suspensions were made from the spleen,
draining lymph nodes, blood and liver of PfCSP-KMY-SAPN
immunized or saline control mice. Livers were perfused with
saline, and lymphocytes were separated from hepatocytes using
Percoll gradient treatment. Red blood cells from the spleen, liver
and blood were lysed using an 8.3 g L21 ammonium chloride
solution. Cells were seeded in 96 well plates with 100 mg
designated peptide or media alone for 5 h in the presence of
GolgiStop. Cells were then harvested and stained for anti-mouse
APC-conjugated anti-TCRb (H57–597), Pacific Blue-conjugated
anti-CD4 (RM4-5), FITC-conjugated anti-CD8a (53–6.7), PE-
Cy5-conjugated anti-CD44 (IM7), PE-conjugated anti-CD62L
(MEL-14), Alexa Fluor 700-conjuagted anti-IFN-c (XMG1.2), and
PE-Cy7-conjugated anti-IL-2 (JES6-5H4) all purchased from BD
Pharmingen and analyzed by flow cytometry. Prior to intracellular
staining with Alexa Fluor 700 anti-IFNc (XMG1.2) and PE-Cy7-
conjugated anti-IL-2 (JES6-5H4), cells were treated with Cytofix/
Cytoperm reagents (BD Pharmingen) per manufacturer’s recom-
mendations.
Statistical Calculations
p-values between groups were calculated using unpaired
students t-test. Evaluation of variance in (Table 1) was done by
1-way ANOVA. Comparison of Kaplan-Meier survival curves
(Figure 5C) were done by log-rank (Mantel-Cox) test using Prism
GraphPad v5.0.
Supporting Information
Figure S1 Representative gating strategy for determi-
nation of cell phenotypes. (A) Cells from their respective
organs were harvested from PfCSP-KMY-SAPN immunized or PBS
sham immunized mice and were selected on a lymphocyte gate
and (B) further characterized for expression of TCRb. (C) TCR b+
cells were subdivided into CD8+ or CD4+ cells. (D) CD8+ T-cells
were characterized as Naı¨ve, TEM, TCM or TLCM based on
expression levels of (E) CD44, CD62L, IL-2 and IFNc. Shown is
determination of TCM.
(TIF)
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Figure S2 In vitro re-stimulation of dendritic cells with
SAPN induces expression of co-stimulatory molecules,
CD40 and CD86. Human dendritic cells were incubated
overnight with media (negative control (Red)), 10 ng (Orange) or
1 ng (Green) LPS as positive controls or 5 mg test SAPN (Blue).
Cells were then stained with markers of co-stimulatory molecules,
CD40 (A) and CD86 (B).
(TIF)
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